References
- Jones R H, Lydeard S E, Hobbs F DR, Kenkre J E, Williams E I, Jones S J, et al. Dyspepsia in England and Scotland. Gut 1990; 31: 401–5
- Nebel O T, Formes M F, Castell D O. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Dig Dis Sci 1976; 21: 953–6
- Howard P J, Heading R C. Epidemiology of gastro‐esophageal reflux disease. World J Surg 1992; 16: 288–93
- Johnsson F, Joelsson B, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987; 22: 714–8
- Berstad A, Weberg R, Frøyshov Larsen I, Hoel B, Hauer‐Jensen M. Relationship of hiatus hernia to reflux oesophagitis. A prospective study of coincidence, using endoscopy. Scand J Gastroenterol 1986; 21: 55–8
- Graham D Y, Lacey Smith J, Patterson D J. Why do apparently healthy people use antacid tablets?. Am J Gastroenterol 1983; 78: 257–60
- Jansen J B.M.J, Baak L C, Lamers C BHW. Effect of increasing doses of ranitidine on exposure of the esophagus to gastric acid in patients with reflux oesophagitis. Scand J Gastroenterol 1988; 23(Suppl 154)2–5
- Aadland E, Berstad A. Effect of cimetidine on pentagastrin‐stimulated gastric acid and pepsin secretion before and after 6 weeks of cimetidine treatment. Scand J Gastroenterol 1978; 13: 193–7
- Prichard P J, Jones D B, Yeomans N D, Mihaly G W, Smallwood R A, Louis W J. The effectiveness of ranitidine in reducing gastric acid‐secretion decreases with continued therapy. Br J Clin Pharmacol 1986; 22: 663–8
- Nwokolo C U, Smith J TL, Gavey C, Sawyerr A, Pounder R E. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990; 4(Suppl 1)29–46
- Smith J TL, Gavey C, Nwokolo C U, Pounder R E. Tolerance during 8 days of high‐dose H2‐blockade: placebo‐controlled studies of 24‐hour acidity and gastrin. Aliment Pharmacol Ther 1990; 4(Suppl 1)47–63
- Wilder‐Smith C, Halter F, Ernst T, Gennoni M, Zeyen B, Varga L, et al. Loss of acid suppression during dosing with H2‐receptor antagonists. Aliment Pharmacol Ther 1990; 4(Suppl 1)15–28
- Hurlimann S, Abbühl B, Inauen W, Halter F. Comparison of acid inhibition of either oral high‐dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193–201
- Bell N JV, Burget D, Howden C W, Wilkinson J, Hunt R H. Appropriate acid suppression for the management of gastro‐oesophageal reflux disease. Digestion 1992; 51(Suppl 1)59–67
- Hatlebakk J G, Berstad A, Carling L, Svedberg L ‐E, Unge P, Ekström P, et al. Lanzoprazole versus omeprazole in short‐term treatment of reflux oesophagitis. Scand J Gastroenterol 1993; 28: 224–8
- Berstad K, Wilhelmsen I, Berstad A. Biometric evaluation of gastric urease activity in man. Scand J Gastroenterol 1992; 28: 224–8
- Wilder‐Smith C H, Halter F, Merki H S. Tolerance and rebound to H2‐receptor antagonists: intragastric acidity in patients with duodenal ulcer. Dig Dis Sci 1991; 36: 1685–90
- Hatlebakk J G, Berstad A. Comparison between the endoscopic picture and parameters of gastro‐esophageal reflux in reflux esophagitis. Gastroenterology 1991; 100: A80
- Lacey Smith J, Opekun A R, Larkai E, Graham D Y. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989; 96: 683–9